Oxigene -

Despite promising science, the company faced periodic financial restructurings, including a significant workforce reduction in 2011 to conserve resources for early-stage programs.

Lead candidate; received and Orphan Drug designations for platinum-resistant ovarian cancer. OXi4503

A key Phase II trial showed that a combination of CA4P and Avastin significantly improved progression-free survival in ovarian cancer patients compared to Avastin alone. Oxigene

The shift to Mateon Therapeutics reflected a broader focus on "Vascular Targeted Therapy" (VTT), which combines VDAs with anti-angiogenic agents to trap and destroy tumor cores while preventing new vessel growth. Historical Acquisitions:

In 2010, OXiGENE acquired VaxGen, Inc. in a stock-for-stock merger to bolster its cash reserves by approximately $33 million. The shift to Mateon Therapeutics reflected a broader

Unlike traditional anti-angiogenic drugs that prevent new vessel formation, OXiGENE’s VDAs targeted existing immature blood vessels within tumors. These agents compromise the tumor's core vasculature, leading to extensive necrosis (cell death) within the center of the tumor.

On June 20, 2016, OXiGENE officially became Mateon Therapeutics (formerly NASDAQ: OXGN, now MATN). OXiGENE acquired VaxGen

OXiGENE, Inc. was a clinical-stage biopharmaceutical company that rebranded as in June 2016. The company specialized in developing Vascular Disrupting Agents (VDAs) designed to selectively dismantle blood vessels that sustain solid tumors and contribute to visual impairment. Corporate Evolution